The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...
Shares of Novo Nordisk ( NVO 4.37%) were moving higher on Wednesday. The company's stock gained 4.9% as of 1:50 p.m. ET, but ...
Novo Nordisk's U.S.-listed shares are rising 4% in premarket trading after the Ozempic and Wegovy maker's better-than-estimated quarterly results offset slower 2025 sales growth projections amid ...
Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...
Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...
On the charts, today's pop has NVO on track to snap a three-day losing streak. The stock still hasn't recovered from its ...
By contrast, those taking a placebo experienced weight gain of up to 2.3%. Amycretin's safety profile, according to Novo Nordisk, was consistent with that of medicines of the same type ...
Novo Nordisk’s Ozempic (semaglutide) has been approved by the US Food and Drug Administration (FDA) to reduce the risk of kidney disease worsening, kidney failure and cardiovascular disease (CVD) ...
The FDA has approved Novo Nordisk’s Ozempic (semaglutide) as the first and only GLP-1 receptor agonist (GLP-1 RA) indicated to reduce the risk of worsening kidney disease, kidney failure, and ...
Roughly 40% of Type 2 diabetes patients have the condition, which can cause additional sickness such as increased risk of cardiovascular problems and death, Novo Nordisk said. "All chronic kidney ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback